Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Oralair Grasses Approved for Adults With Allergic Rhinoconjunctivitis in Germany - (DGNews)
    Cockroach Immunotherapy Effective in Patients With Allergic Rhinitis, Asthma: Presented at EAACI - (DGDispatch)
    Subcutaneous and Sublingual Therapies Equally Effective in Treating Tree- and Grass-Pollen-Related Rhinoconjunctivitis: Presented at EAACI - (DGDispatch)
    Sublingual Tablets Provide Effective and Safe Immunotherapy for Grass Pollen Allergy: Presented at EAACI - (DGDispatch)
    Sublingual Immunotherapy With Aqueous Vaccine Controls Allergic Diseases: Presented at EAACI - (DGDispatch)

    News archive

     Recent webcasts/CME - Allergy Other
    • Improving Outcomes for Patients With Allergic Rhinitis: An Update From Philadelphia
    • Safety and Efficacy of Novel Agents in Allergic Rhinitis: An Update From AAAAI
    • Understanding the Impact of Allergic Rhinitis on Quality of Life
    • Food Allergies: When the Food Comes to Bite the Gut
      Allergic Rhinitis in Adults and Children

      Webcasts/CME archive

       Recent cases - Allergy Other
        Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report
        Food-Dependent Exercise-Induced Anaphylaxis Induced by Low Dose Aspirin Therapy
        Allergic Hemiglossitis as a Unique Case of Food Allergy : A Case Report
        Severe Generalised Hypersensitivity Reaction to Topical Neomycin After Cataract Surgery: A Case Report
        Cellphone Contact Dermatitis with Nickel Allergy

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        FDA Approves Clarinex (Desloratadine) Syrup for Relief of Symptoms Associated With Indoor and Outdoor Allergies and Hives in Children

        -- Indoor Allergies and Hives for Children Six Months and Older -- Outdoor Allergies for Children Two Years and Older


        KENILWORTH, NJ -- September 2, 2004 -- Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Clarinex® (desloratadine) Syrup for the relief of symptoms associated with seasonal allergic rhinitis (SAR) (outdoor allergies) in children two years and older and perennial allergic rhinitis (PAR) (indoor allergies) and chronic idiopathic urticaria (CIU), or hives of unknown cause in children as young as six months. The approval of the CIU and PAR indications makes it the only prescription non-sedating antihistamine syrup on the market for a patient population as young as six months. The new Clarinex Syrup is expected to be available in the U.S. during the first half of 2005.


        Clinical Trials
        The FDA approval of the new Clarinex Syrup results from three double- blind, placebo-controlled safety studies involving 246 pediatric subjects six months to 11 years of age with a documented history of allergic rhinitis, chronic idiopathic urticaria, or subjects who were candidates for antihistamine therapy. The results of these studies demonstrated the safety of Clarinex Syrup in pediatric subjects six months to 11 years of age.

        In clinical trials, the overall incidence of adverse events in children six years through 11 years of age was similar for the desloratadine syrup and the placebo groups. In pediatric patients six months to five years of age, the most frequently seen adverse events were upper respiratory tract infection, diarrhea, fever, urinary tract infection, varicella, irritability and coughing. Full prescribing information is available at: http://www.spfiles.com/piclarinex.pdf.


        SOURCE: Schering-Plough Corporation



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send